Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as GBX 2,166 ($26.99) and last traded at GBX 2,166 ($26.99), with a volume of 279808 shares traded. The stock had previously closed at GBX 2,130 ($26.55).
Hikma Pharmaceuticals Price Performance
The company has a debt-to-equity ratio of 55.48, a current ratio of 1.66 and a quick ratio of 1.27. The firm has a market capitalization of £4.82 billion, a P/E ratio of 3,341.54, a PEG ratio of 2.38 and a beta of 0.41. The company's 50 day moving average price is GBX 1,978.79 and its 200 day moving average price is GBX 1,939.56.
About Hikma Pharmaceuticals
(
Get Free Report)
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.
Featured Stories
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
